Tofacitinib (CP-690.550)

Name Value
Weight 312.377 g/mol
Zinc ID ZINC3818808
Smiles C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Molecular formula C16H20N6O
Mode of inhibition Direct JAK3, STAT; Tyrosine kinase inhibitor
CAS 477600-75-2

Clinical Trials

Study title Status Conditions Link
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Active, not recruiting Alopecia Areata NCT03800979
Study of Tofacitinib in Refractory Dermatomyositis Active, not recruiting Dermatomyositis NCT03002649
IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis Recruiting Arthritis, Rheumatoid NCT03981900
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Recruiting Takayasu Arteritis|Methotrexate|Inhibition|Treatment NCT04299971
Tofacitinib for Immune Skin Conditions in Down Syndrome Not yet recruiting Down Syndrome|Alopecia|Atopic Dermatitis/Eczema|Hidradenitis Suppurativa|Vitiligo|Psoriasis NCT04246372
A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants. Completed Healthy NCT04111614
Tofacitinib in Depression (TIDE) Recruiting Depression|Inflammation NCT04141904
Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease Not yet recruiting Rheumatoid Arthritis|Interstitial Lung Disease Due to Systemic Disease (Disorder) NCT04311567
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis Completed Psoriatic Arthritis NCT03736161
Tofacitinib for Inflammatory Eye Disease Active, not recruiting Uveitis|Scleritis NCT03580343
Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed Alopecia Areata|Alopecia Totalis|Alopecia Universalis NCT02312882
Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh Recruiting Spondyloarthritis NCT03504072
Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis Recruiting Rheumatoid Arthritis NCT03011281
Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare Recruiting Cutaneous Sarcoidosis|Granuloma Annulare NCT03910543
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Completed Systemic Sclerosis|Scleroderma NCT03274076
A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT02281552
Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers Completed Rheumatoid Arthritis NCT03868072
Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Recruiting Cutaneous Lupus|Systemic Lupus Erythematosus NCT03288324
Efficacy Study Of Tofacitinib In Pediatric JIA Population Completed Juvenile Idiopathic Arthritis NCT02592434
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Completed Alopecia Areata NCT02299297
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed Alopecia Areata|Alopecia Totalis|Alopecia Universalis NCT02812342
An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective Completed Rheumatoid Arthritis NCT02566967
Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project Not yet recruiting Rheumatoid Arthritis NCT04175886
Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study Enrolling by invitation Ulcerative Colitis NCT03772145
Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Recruiting Discoid Lupus Erythematosus|Systemic Lupus Erythematosus NCT03159936
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus Completed Systemic Lupus Erythematosus NCT02535689
Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement Not yet recruiting Psoriatic Arthritis|Spondylitis|Sacroilitis NCT04062695
A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers Completed Healthy NCT02487433
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis Recruiting Arthritis, Rheumatoid NCT03387423
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial Recruiting Axial Spondyloarthritis NCT03738956
Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients Completed Rheumatoid Arthritis NCT02321930
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis Recruiting Psoriatic Arthritis NCT03486457
A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers Completed Healthy NCT02084875
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA Recruiting Arthritis Juvenile Idiopathic NCT03000439
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis Recruiting Juvenile Idiopathic Arthritis NCT01500551
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Recruiting Neoplasms With Mesothelin Expression|Epithelioid Mesothelioma|Cholangiocarcinoma, Extrahepatic|Adenocarcinoma, Pancreatic NCT04034238
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT02831855
Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers Recruiting Healthy Volunteers NCT04114461
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS) Active, not recruiting Ankylosing Spondylitis NCT03502616
A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate Completed Rheumatoid Arthritis NCT02147587
A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers Completed Healthy NCT01731327
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis Recruiting Sarcoidosis, Pulmonary|Sarcoidosis Lung|Sarcoidosis NCT03793439
Tofacitinib Combined With Chidamide in R/R ENKTCL Not yet recruiting Extranodal NK/T-cell Lymphoma NCT03598959
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis Completed Arthritis, Psoriatic NCT01976364
A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers Completed Healthy NCT01499004
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate Completed Rhematoid Arthritis NCT02187055
Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT01164579
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) Completed Dermatitis, Atopic NCT02001181
Tofacitinib Bioequivalence Study Comparing Tablets And Capsules Completed Healthy NCT01599377
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis Completed Ankylosing Spondylitis NCT01786668
Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers Completed Healthy NCT01202240
Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis Active, not recruiting Rheumatoid Arthritis NCT01932372
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) Recruiting Arthritis, Rheumatoid NCT03970837
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors Completed Psoriatic Arthritis NCT01882439
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Recruiting Arthritis, Rheumatoid NCT03980483
JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction Recruiting Diaphragm Injury NCT03681275
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany Recruiting Colitis, Ulcerative|Biologics|Tofacitiniib|Chronic Inflammatory Small Bowel Disease|Bowel Diseases, Inflammatory|Bowel Disease|CED NCT04032756
Tofacitinib Ointment For Chronic Plaque Psoriasis Completed Psoriasis Vulgaris|Psoriasis NCT01831466
Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples Recruiting Ulcerative Colitis NCT03663400
Tofacitnib for the Treatment of Alopecia Areata and Variants Completed Alopecia Areata (AA)|Alopecia Totalis (AT)|Alopecia Universalis (AU) NCT02197455
Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib Recruiting Inflammatory Bowel Diseases NCT03591770
A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day Completed Arthritis Rheumatoid NCT04267380
Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics Active, not recruiting Arthritis, Rheumatoid NCT03964649
Evaluation of Pain Sensitization in Rheumatoid Arthritis: Analysis on a Cohort of Tofacitinib Treated Patients Recruiting Rheumatoid Arthritis NCT03815578
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis Active, not recruiting Arthritis, Rheumatoid NCT02092467
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study Completed Psoriatic Arthritis NCT01877668
PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations Completed Healthy NCT03112148
Examination of Efficacy and Safety of Baricitinib in RA Patients Recruiting Rheumatoid Arthritis NCT03755466
Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients Completed Kidney Transplantation NCT01375127
Changes of Depression After First-year of Tofacitinib in RA Patients Not yet recruiting Rheumatoid Arthritis NCT03992781
Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients Not yet recruiting Rheumatoid Arthritis NCT04079920
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Completed Rheumatoid Arthritis NCT03975790
A Study Of Tasocitinib In Dry Eye Subjects Withdrawn Keratoconjunctivitis Sicca NCT01226680
Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR) Completed Rheumatoid Arthritis NCT04018001
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions Completed Arthritis, Rheumatoid NCT03073109
A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects Completed Rheumatoid Arthritis NCT01184001
Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01262118
Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate Completed Rheumatoid Arthritis NCT02996500
A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550) Completed Rheumatoid Arthritis NCT01184092
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC) Completed Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects NCT03103412
Rheumatoid Arthritis Satisfaction Outcome Research Recruiting Rheumatoid Arthritis NCT03703817
Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers Completed Healthy NCT01204112
Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients Not yet recruiting Ulcerative Colitis NCT04071405
Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Rheumatoid Arthritis NCT02157012
Advanced Therapeutics in Rheumatoid Arthritis (RA) Recruiting Rheumatoid Arthritis NCT03976245
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission Active, not recruiting Ulcerative Colitis NCT03281304
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis Completed Ulcerative Colitis NCT01465763
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis Completed Ulcerative Colitis NCT01458951
A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form Completed Healthy NCT01143805
Xeljanz Special Investigation for Long-term Use in UC Patients Active, not recruiting Ulcerative Colitis NCT03643211
Korean Post-marketing Surveillance for Xeljanz Recruiting Rheumatoid Arthritis|Psoriatic Arthritis NCT02984020
Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Active, not recruiting Herpes Zoster NCT03016884
Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA) Completed Juvenile Idiopathic Arthritis NCT01513902
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis Completed Arthritis, Rheumatoid NCT00413699
Senica MUDr. Pavol Polak s.r.o. Slovakia|Hospital Nuestra Senora de la Esperanza Nestatne zdravotnicke zariadenie
Co-Administration Of Methotrexate And CP-690,550 Completed Rheumatoid Arthritis NCT01745055
A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients Completed Rheumatoid Arthritis NCT04047121
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 Completed Rheumatoid Arthritis NCT01741493
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis Completed Psoriasis Vulgaris NCT02193815
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis Completed Plaque Psoriasis NCT01710046
A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis Completed Arthritis, Rheumatoid NCT01484561
The Safety And Efficacy Of Maintenance Therapy With CP-690,550 Completed Crohn's Disease NCT01393899
Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients Recruiting Rheumatoid Arthritis NCT03440892
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis Completed Psoriasis|Immunomodulation NCT01736696
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients Completed Kidney Transplantation NCT00106639
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan Completed Rheumatoid Arthritis NCT00661661
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis Terminated Psoriasis NCT01163253
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient Completed Kidney Transplantation NCT00263328
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease Completed Crohn's Disease NCT01393626
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis Completed Psoriasis NCT01815424
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis Completed Psoriasis NCT01309737
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis Completed Psoriasis NCT01276639
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis Completed Psoriasis NCT01519089
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis Completed Ulcerative Colitis NCT01458574
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis Completed Psoriasis NCT01186744
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients Completed Kidney Transplantation NCT00658359
The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis Unknown status Psoriasis NCT01504113
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis Completed Psoriasis NCT01241591
JAKPOT (JAK Inhibitors and Predictors of Outcome in rheumaToid Arthritis) Recruiting Rheumatoid Arthritis NCT04084223
Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function Completed Renal Impairment NCT01740362
A Study Of CP-690,550 In Stable Kidney Transplant Patients Completed Kidney Transplant NCT01710033
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease Completed End-Stage Renal Disease|Hemodialysis NCT01710020
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis Active, not recruiting Ulcerative Colitis NCT01470612
A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease Completed Crohn's Disease NCT01470599
A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550 Completed Arthritis, Rheumatoid NCT01277991
CP-690-550 Ointment For Chronic Plaque Psoriasis Completed Psoriasis NCT01246583
Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers Completed Healthy NCT01185184
CP-690,550 Pharmacokinetics In Healthy Chinese Subjects Completed Healthy NCT01101919
A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers Completed Arthritis, Rheumatoid NCT01023100
A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function Completed Hepatic Insufficiency NCT00969813
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications Completed Arthritis, Rheumatoid NCT00856544
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis Completed Arthritis, Rheumatoid NCT00814307
Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan Completed Arthritis, Rheumatoid NCT00687193
Topical CP-690,550 For Chronic Plaque Psoriasis Completed Psoriasis NCT00678561
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed Psoriasis NCT00678210
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease Completed Crohn's Disease NCT00615199
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers Completed Rheumatoid Arthritis NCT03858725
Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550 Completed Arthritis, Rheumatoid NCT00414661
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks Completed Rheumatoid Arthritis NCT00147498
In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma Completed Asthma NCT02740049
Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers Completed Rheumatoid Arthritis NCT01405118
Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550 Completed Rheumatoid Arthritis NCT01059864
A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00976599
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors Completed Arthritis, Rheumatoid NCT00960440
CP-690,550 and Midazolam Drug-Drug Interaction Study Completed Healthy Volunteer NCT00902460
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00853385
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate Completed Arthritis, Rheumatoid NCT00847613
Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan Completed Arthritis, Rheumatoid NCT00603512
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis Completed Arthritis, Rheumatoid NCT00550446
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis Completed Arthritis, Rheumatoid NCT00413660
A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA) Unknown status Rheumatoid Arthritis NCT02797769
Determination of the Optimal Treatment Target in Ulcerative Colitis Recruiting Colitis, Ulcerative NCT04259138
A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease Completed Dry Eye Syndromes NCT01135511
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX Completed Arthritis, Rheumatoid NCT01039688
CP-690,550 Thorough QTc Study Completed Healthy NCT01743677
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye. Completed Dry Eye Syndromes NCT00784719
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients Completed Kidney Transplantation NCT00483756
CP-690,550 And Oral Contraception Drug-Drug Interaction Study Completed Healthy NCT01137708
A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo Completed Rheumatoid Arthritis NCT01359150
A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers Completed Healthy Volunteers NCT00860496
A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants Recruiting Colitis, Ulcerative|Crohn Disease NCT03710486
Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management Completed Rheumatoid Arthritis NCT02820038

References

Publication DOI Pubmed PMCID
Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochemical and biophysical research communications Hideyuki Yoshida, Akihiro Kimura, Tomohiro Fukaya, Takashi Sekiya, Rimpei Morita, Takashi Shichita, Hiromasa Inoue, Akihiko Yoshimura, 418, 2, 2012-02-10, 2012-01-09, 10.1016/j.bbrc.2011.12.156 10.1016/j.bbrc.2011.12.156 22252297 22252297
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Annals of the rheumatic diseases Sanna Rosengren, Maripat Corr, Gary S Firestein, David L Boyle, 71, 3, None, 2011-11-25, 10.1136/ard.2011.150284 10.1136/ard.2011.150284 22121136 22121136
Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. British journal of cancer X Zhang, M A Blaskovich, K D Forinash, S M Sebti, 111, 5, 2014-08-26, 2014-07-01, 10.1038/bjc.2014.349 10.1038/bjc.2014.349 24983364 PMC4150266

Vendors

Company Lnk to product
Selleckchem https://www.selleckchem.com/products/CP-690550.html
MedChemExpress https://www.medchemexpress.com/Tofacitinib.html
Adooq https://www.adooq.com/cp-690550-tofacitinib-citrate.html
Tocris https://www.tocris.com/products/cp-690550-citrate_4556
BLDpharm https://www.bldpharm.com/products/477600-75-2.html

Filter data

Compound Tofacitinib (CP-690.550)
Experiment types Arthritis score , ELISA, Flow cytometry , Intracellular staining, Mean Clinical Score, Real-time TaqMan PCR, Western Blot, [3H] thymidine incorporation
Concentrations 0.30, 10.00, 100.00, 1000.00, 15.00, 200.00, 3.00, 30.00, 300.00, 50.00
Cell lines FLS, HEK293T, Naïve CD4+ T
Organisms Homo sapiens, Mus musculus
Animal models DBA/1, c57BL/6
STAT proteins STAT1, STAT3, STAT5, STAT6, p-STAT1, p-STAT3, p-STAT5, p-STAT6
Other GAPDH, IL-10 - IL17A, IL-17A - Foxp3, IL-4 - IFNγ, IL-6, IL8, IP10, MCP1, Myc, RANTES, SMAD2, TNF-α, p-SMAD2

Experiments

Compound Experiment type Investigated event Concentration Cell line Organism Animal model Stat protein Details
Tofacitinib (CP-690.550) Arthritis score Influence on arthritis development 15.00 mg/kg/day Mus musculus DBA/1
Tofacitinib (CP-690.550) ELISA Influence on cytokine levels in serum 15.00 mg/kg/day Mus musculus DBA/1
Tofacitinib (CP-690.550) ELISA Influence on cytokine levels in serum 15.00 mg/kg/day Mus musculus DBA/1
Tofacitinib (CP-690.550) Mean Clinical Score Influence on EAE development 15.00 mg/kg/day Mus musculus DBA/1
Tofacitinib (CP-690.550) Flow cytometry Influence on cytokine levels in CNS 15.00 mg/kg/day Mus musculus DBA/1
Tofacitinib (CP-690.550) [3H] thymidine incorporation Influence on Th differentiation 10.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) [3H] thymidine incorporation Influence on Th differentiation 30.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) [3H] thymidine incorporation Influence on Th differentiation 100.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Intracellular staining Influence on Th1 differentiation 10.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Intracellular staining Influence on Th1 differentiation 50.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Intracellular staining Influence on Th2 differentiation 10.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Intracellular staining Influence on Th2 differentiation 50.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Intracellular staining Influence on Th17 differentiation 10.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Intracellular staining Influence on Th17 differentiation 50.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Intracellular staining Influence on Th17 differentiation 10.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Intracellular staining Influence on Th17 differentiation 100.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 10.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 10.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 10.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 10.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 10.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 10.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 10.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of TGF-β and IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IFNγ 0.30 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IFNγ 3.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IFNγ 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IFNγ 0.30 nM Naïve CD4+ T Mus musculus c57BL/6 STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IFNγ 3.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IFNγ 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-4 0.30 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-4 3.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-4 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-4 0.30 nM Naïve CD4+ T Mus musculus c57BL/6 STAT6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-4 3.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-4 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT6
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-2 0.30 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-2 3.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-2 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 0.30 nM Naïve CD4+ T Mus musculus c57BL/6 STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 3.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT5
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 300.00 nM Naïve CD4+ T Mus musculus c57BL/6 p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 30.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 100.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in presence of IL-6 300.00 nM Naïve CD4+ T Mus musculus c57BL/6 STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in transfecfected cells 30.00 nM HEK293T Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in transfecfected cells 100.00 nM HEK293T Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in transfecfected cells 300.00 nM HEK293T Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in transfecfected cells 1000.00 nM HEK293T Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in transfecfected cells 30.00 nM HEK293T Homo sapiens
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in transfecfected cells 100.00 nM HEK293T Homo sapiens
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in transfecfected cells 300.00 nM HEK293T Homo sapiens
Tofacitinib (CP-690.550) Western Blot Influence on protein activity in transfecfected cells 1000.00 nM HEK293T Homo sapiens
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 30.00 nM FLS Homo sapiens p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 100.00 nM FLS Homo sapiens p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 300.00 nM FLS Homo sapiens p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 1000.00 nM FLS Homo sapiens p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 30.00 nM FLS Homo sapiens STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 100.00 nM FLS Homo sapiens STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 300.00 nM FLS Homo sapiens STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 1000.00 nM FLS Homo sapiens STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 30.00 nM FLS Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 100.00 nM FLS Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 300.00 nM FLS Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 1000.00 nM FLS Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 30.00 nM FLS Homo sapiens STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 100.00 nM FLS Homo sapiens STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 300.00 nM FLS Homo sapiens STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 1000.00 nM FLS Homo sapiens STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 30.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 100.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 300.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of IL-6 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) ELISA Influence on cytokine secretion in presence of IL-6 200.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) ELISA Influence on cytokine secretion in presence of IL-6 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) Real-time TaqMan PCR Influence on mRNA expression 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) Real-time TaqMan PCR Influence on mRNA expression 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) Real-time TaqMan PCR Influence on mRNA expression 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) Real-time TaqMan PCR Influence on mRNA expression 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) ELISA Influence on cytokine secretion in presence of TNF 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) ELISA Influence on cytokine secretion in presence of TNF 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) ELISA Influence on cytokine secretion in presence of TNF 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) ELISA Influence on cytokine secretion in presence of TNF 1000.00 nM FLS Homo sapiens
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of TNF 1000.00 nM FLS Homo sapiens p-STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of TNF 1000.00 nM FLS Homo sapiens STAT1
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of TNF 1000.00 nM FLS Homo sapiens p-STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of TNF 1000.00 nM FLS Homo sapiens STAT3
Tofacitinib (CP-690.550) Western Blot Influence on protein acticity in presence of TNF 1000.00 nM FLS Homo sapiens